Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K)

AIDS

Volumn 21, Issue 4, 2007, Pages 519-521

  Tolstrup, Martin ^a,b   Selzer Plön, Joanna ^a   Laursen, Alex L ^a   Bertelsen, Lone ^a   Gerstoft, Jan ^c   Duch, Mogens ^b   Pedersen, Finn S ^b   Ostergaard, Lars ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN; PROTEINASE INHIBITOR;

ARTICLE; EVOLUTION; FOLLOW UP; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHENOTYPE; PRIORITY JOURNAL; VIRUS ENVELOPE;

DRUG RESISTANCE, VIRAL; GENOTYPE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PEPTIDE FRAGMENTS; POLYMORPHISM, GENETIC;

EID: 33847020059     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3280187558     Document Type: Article

References (15)

1. Servais J, Plesseria JM, Lambert C, Fontaine E, Robert I, Arendt V, et al. Genotypic correlates of resistance to HIV-1 protease inhibitors on longitudinal data: the role of secondary mutations. Antivir Ther 2001; 6:239-248.
2. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-480.
3. Weber J, Rangel HR, Chakraborty B, Marotta ML, Valdez H, Fransen K, et al. Role of baseline pol genotype in HIV-1 fitness evolution. J Acquir Immune Defic Syndr 2003; 33:448-460.
4. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195.
5. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89:263-273.
6. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4:1302-1307.
7. Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, et al. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 2004; 48:3253-3259.
8. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-1905.
9. Melby T, Sista P, Demasi R, Kirkland T, Roberts N, Salgo M, et al. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses 2006; 22:375-385.
10. Letiner T, Foley B, Hahn B, Marx P, McCutchan F, Mellors J, et al. HIV sequence compendium 2005. LA-UR 06-0690. Theoretical Biology and Biophysics Group. New Mexico: Los Alamos National Laboratory; 2005.
11. Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labernardiere JL, Pacanowski J, et al. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol 2006; 80:8807-8819.
12. Jenwitheesuk E, Samudrala R. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure. Antivir Ther 2005; 10:893-900.
13. Perez-Alvarez L, Carmona R, Ocampo A, Asorey A, Miralles C, Perez de CS, et al. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1. J Med Virol 2006; 78:141-147.
14. Poveda E, Rodes B, Lebel-Binay S, Faudon JL, Jimenez V, Soriano V. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. J Clin Virol 2005; 34:295-301.
15. Xu L, Pozniak A, Wildfire A, Stanfield-Oakley SA, Mosier SM, Ratcliffe D, et al. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 2005; 49:1113-1119.